These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists. Dowling JE; Vessels JT; Haque S; Chang HX; van Vloten K; Kumaravel G; Engber T; Jin X; Phadke D; Wang J; Ayyub E; Petter RC Bioorg Med Chem Lett; 2005 Nov; 15(21):4809-13. PubMed ID: 16153830 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists. Shah U; Lankin CM; Boyle CD; Chackalamannil S; Greenlee WJ; Neustadt BR; Cohen-Williams ME; Higgins GA; Ng K; Varty GB; Zhang H; Lachowicz JE Bioorg Med Chem Lett; 2008 Jul; 18(14):4204-9. PubMed ID: 18558486 [TBL] [Abstract][Full Text] [Related]
27. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites. Michielan L; Bolcato C; Federico S; Cacciari B; Bacilieri M; Klotz KN; Kachler S; Pastorin G; Cardin R; Sperduti A; Spalluto G; Moro S Bioorg Med Chem; 2009 Jul; 17(14):5259-74. PubMed ID: 19501513 [TBL] [Abstract][Full Text] [Related]
28. Antagonists of the human A(2A) receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides. Gillespie RJ; Bamford SJ; Gaur S; Jordan AM; Lerpiniere J; Mansell HL; Stratton GC Bioorg Med Chem Lett; 2009 May; 19(10):2664-7. PubMed ID: 19362836 [TBL] [Abstract][Full Text] [Related]
29. 2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents. Slee DH; Chen Y; Zhang X; Moorjani M; Lanier MC; Lin E; Rueter JK; Williams JP; Lechner SM; Markison S; Malany S; Santos M; Gross RS; Jalali K; Sai Y; Zuo Z; Yang C; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Saunders J J Med Chem; 2008 Mar; 51(6):1719-29. PubMed ID: 18307292 [TBL] [Abstract][Full Text] [Related]
30. Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists. Shook BC; Rassnick S; Chakravarty D; Wallace N; Ault M; Crooke J; Barbay JK; Wang A; Leonard K; Powell MT; Alford V; Hall D; Rupert KC; Heintzelman GR; Hansen K; Bullington JL; Scannevin RH; Carroll K; Lampron L; Westover L; Russell R; Branum S; Wells K; Damon S; Youells S; Beauchamp D; Li X; Rhodes K; Jackson PF Bioorg Med Chem Lett; 2010 May; 20(9):2868-71. PubMed ID: 20338760 [TBL] [Abstract][Full Text] [Related]
31. Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease. Shook BC; Rassnick S; Wallace N; Crooke J; Ault M; Chakravarty D; Barbay JK; Wang A; Powell MT; Leonard K; Alford V; Scannevin RH; Carroll K; Lampron L; Westover L; Lim HK; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Rhodes K; Jackson PF J Med Chem; 2012 Feb; 55(3):1402-17. PubMed ID: 22239465 [TBL] [Abstract][Full Text] [Related]
32. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. Cosimelli B; Greco G; Ehlardo M; Novellino E; Da Settimo F; Taliani S; La Motta C; Bellandi M; Tuccinardi T; Martinelli A; Ciampi O; Trincavelli ML; Martini C J Med Chem; 2008 Mar; 51(6):1764-70. PubMed ID: 18269230 [TBL] [Abstract][Full Text] [Related]
33. Differential effects of adenosine antagonists in two models of parkinsonian tremor. Trevitt J; Kawa K; Jalali A; Larsen C Pharmacol Biochem Behav; 2009 Nov; 94(1):24-9. PubMed ID: 19602422 [TBL] [Abstract][Full Text] [Related]
34. Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease. Volpini R; Dal Ben D; Lambertucci C; Marucci G; Mishra RC; Ramadori AT; Klotz KN; Trincavelli ML; Martini C; Cristalli G ChemMedChem; 2009 Jun; 4(6):1010-9. PubMed ID: 19343763 [TBL] [Abstract][Full Text] [Related]
35. 2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A(2A) antagonists with improved solubility and metabolic stability. Moorjani M; Luo Z; Lin E; Vong BG; Chen Y; Zhang X; Rueter JK; Gross RS; Lanier MC; Tellew JE; Williams JP; Lechner SM; Malany S; Santos M; Crespo MI; Díaz JL; Saunders J; Slee DH Bioorg Med Chem Lett; 2008 Oct; 18(20):5402-5. PubMed ID: 18835161 [TBL] [Abstract][Full Text] [Related]
37. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Pinna A; Wardas J; Simola N; Morelli M Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104 [TBL] [Abstract][Full Text] [Related]
39. Identification of a New Series of Potent Adenosine A Yang Z; Li L; Zheng J; Ma H; Tian S; Li J; Zhang H; Zhen X; Zhang X ACS Chem Neurosci; 2016 Nov; 7(11):1575-1584. PubMed ID: 27569066 [TBL] [Abstract][Full Text] [Related]
40. Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists. Yao G; Haque S; Sha L; Kumaravel G; Wang J; Engber TM; Whalley ET; Conlon PR; Chang H; Kiesman WF; Petter RC Bioorg Med Chem Lett; 2005 Feb; 15(3):511-5. PubMed ID: 15664803 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]